Drug for Dialysis-related Amyloidosis
Compounds already have a proven safety profile Treatment for DRA would occur during normal dialysis treatment directly into patient blood where fibrils are found
Treatment of dialysis-related amyloidosis It is anticipated the drug could be added to the dialysis solutions given to dialysis patients to treat or prevent DRA The assay may be used to identify drugs that dissolve fibrils associated with other human diseases
Researchers at UCLA have identified 2 compounds that disrupt preformed human -2 microglobulin fibrils in a dose-dependent manner at concentrations that are clinically relevant. Both of these compounds have been proven safe in clinical trials for other diseases and could be readily administered during dialysis. These compounds were identified using a high throughput screen developed by the researchers for the identification of drugs that dissolve fibrils. The developed assay can be used to find drugs that dissolve fibrils associated with other human diseases.
Patent Number: EP2300048A4
Application Number: EP2009737621A
Inventor: XU AIMIN | WANG YU | RENNEBERG REINHARD | CAUTHERLEY GEORGE WILLIAM HUNTER | CHAN PUIYEE CANGEL | LEHMANN MATTHIAS
Priority Date: 30 Apr 2008
Priority Number: EP2300048A4
Application Date: 16 Apr 2009
Publication Date: 24 Aug 2011
IPC Current: A61K003843 | A61P000900 | C07K001447 | G01N003353
Assignee Applicant: Versitech Ltd | R & C Biogenius Ltd
Title: LIPOCALIN-2 AS A PROGNOSTIC AND DIAGNOSTIC MARKER FOR HEART AND STROKE RISKS | LIPOCALIN-2 ALS PROGNOSTISCHER UND DIAGNOSTISCHER MARKER FÜR HERZ- UND SCHLAGANFALLRISIKEN | LIPOCALINE 2 EN TANT QUE MARQUEUR PRONOSTIQUE ET DIAGNOSTIQUE DE RISQUES CARDIAQUES
Usefulness: LIPOCALIN-2 AS A PROGNOSTIC AND DIAGNOSTIC MARKER FOR HEART AND STROKE RISKS | LIPOCALIN-2 ALS PROGNOSTISCHER UND DIAGNOSTISCHER MARKER FÜR HERZ- UND SCHLAGANFALLRISIKEN | LIPOCALINE 2 EN TANT QUE MARQUEUR PRONOSTIQUE ET DIAGNOSTIQUE DE RISQUES CARDIAQUES ET D ACCIDENT CÉRÉBROVASCULAIRE
诊断/治疗
其他疾病
9463195
Background Amyloid formation plays a role in over 20 human diseases including Alzheimers disease, type II diabetes and the systemic amyloidoses. Dialysis-related amyloidosis (DRA) occurs in dialysis patients when -2 microglobulin builds up in the blood and deposits in the joints as amyloid. DRA eventually affects all long-term kidney dialysis patients and is only effectively treated by kidney transplant; if left untreated, the systemic amyloidosis can be deadly. Over 300,000 people in the United States and over 1 million worldwide are on kidney or peritoneal dialysis. Finding a treatment to dissolve the -2 microglobulin fibrils would provide the only alternative to a kidney transplant for these patients. Additional Technologies by these Inventors Tech ID/UC Case 20142/2006-584-0 Related Cases 2006-584-0
美国
